SAN DIEGO, Sept. 28, 2017 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) announced today that the company will present a poster on its antifungal VL-2397 development program at the Infectious Diseases Society of America (IDSA) IDWeek 2017, being held in San Diego, CA, from October 4 to 8, 2017. The poster session will be on Friday October 6th from 12:30 to 2:00 pm.
The title of the presentation is “Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis”. The analysis concluded that a 600 milligram dose of VL-2397 administered once daily will provide adequate target attainment. The analysis will serve as the basis for using this dosing regimen in Vical’s upcoming Phase 2 trial in patients with invasive aspergillosis.
Vical also announced today that the company will provide an update on VL-2397 at the 8th Trends in Medical Mycology (TIMM) Conference, being held in Belgrade, Serbia, from October 6 to 9, 2017. The presentation will be on October 8th at 2:15 pm CET.
Vical plans to conduct a Phase 2 efficacy study to evaluate VL-2397 for the treatment of invasive aspergillosis and is working with clinical experts and the FDA towards this objective. The FDA has granted Vical Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designations to VL-2397 for the treatment of invasive aspergillosis. Under the QIDP designation Vical has been interacting with the FDA on the design of the Phase 2 trial and in exploring an expedited development pathway for VL‑2397.
VL-2397 is Vical’s novel antifungal compound that was licensed from Astellas Pharma in 2015. VL-2397 was isolated from a leaf litter fungus collected in a Malaysian national park and represents the first agent in a potentially new class of antifungal drugs.
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include anticipated developments in clinical programs, including the plans, timing of initiation, and enrollment for clinical trials. Risks and uncertainties include whether Vical or others will continue development of VL-2397; whether Vical will be able to obtain regulatory allowances or guidance necessary to proceed with proposed clinical trials or implement anticipated clinical trial designs; whether on-going or planned clinical trials will be initiated or completed on the timelines Vical currently expects, whether any product candidates will be shown to be safe and efficacious in clinical trials; whether Vical will have access to sufficient capital to fund its planned development activities; whether Vical will seek or gain approval to market any product candidates; and additional risks set forth in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.